12 Spinal Muscular Atrophy Clinical Trials in Springdale, AR (2026)

Q: How do I join a clinical trial in Springdale?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Springdale research site will contact you.

Recruiting Spinal Muscular Atrophy Studies in Springdale

NCT06692738Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with metastatic squam...

Springdale, ARPHASE31,160 participantsAstraZeneca

View Study Details

NCT04389632Recruiting

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will ...

Springdale, ARPHASE11,006 participantsSeagen, a wholly owned subsidiary of Pfizer

View Study Details

NCT07144280Recruiting

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression gr...

Springdale, ARPHASE3680 participantsPfizer

View Study Details

NCT06875310Recruiting

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemothera...

Springdale, ARPHASE3630 participantsMirati Therapeutics Inc.

View Study Details

NCT04613596Recruiting

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and ...

Springdale, ARPHASE2626 participantsMirati Therapeutics Inc.

View Study Details

NCT07063745Recruiting

A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

The purpose of this study is to compare the clinical benefit of the combination of BMS-986504 (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus p...

Springdale, ARPHASE2590 participantsBristol-Myers Squibb

View Study Details

NCT07226999Recruiting

Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer

This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to adults with extensive-stage small cell lung cancer (ES-SCLC), a fas...

Springdale, ARPHASE2550 participantsPfizer

View Study Details

NCT07625644Recruiting

BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)

The objective of the study is to evaluate the efficacy and safety of BL-M14D1 in combination with Atezolizumab compared to Standard-of-Care Therapy in adult participants with previously untreated exte...

Springdale, ARPHASE3550 participantsSystImmune Inc.

View Study Details

NCT06203210Recruiting

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

This study was designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC)....

Springdale, ARPHASE3540 participantsDaiichi Sankyo

View Study Details

NCT06745908Recruiting

ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer

This is a randomized, open-label, phase 3 clinical trial to compare the efficacy and safety of N-803 plus tislelizumab and docetaxel (experimental arm) versus docetaxel monotherapy (control arm). Enro...

Springdale, ARPHASE3507 participantsImmunityBio, Inc.

View Study Details

NCT07155187Recruiting

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells in the lungs grow out of control. The purpose of this study is to assess adverse events and change in disease ac...

Springdale, ARPHASE2490 participantsAbbVie

View Study Details

NCT07227298Recruiting

Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

This study is being done to learn more about a new medicine called PF-08634404 and how it works when used with other cancer medicines in people who have advanced solid tumors. An advanced solid tumor ...

Springdale, ARPHASE1162 participantsPfizer

View Study Details

About Spinal Muscular Atrophy Clinical Trials in Springdale

Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder that causes loss of motor neurons, leading to progressive muscle weakness and atrophy. It is the leading genetic cause of infant death. Revolutionary gene therapies and SMN-enhancing drugs have transformed treatment.

There are currently 12 spinal muscular atrophy clinical trials recruiting participants in Springdale, AR. These studies are seeking a combined 7,491 participants. Research is being sponsored by AstraZeneca, Seagen, a wholly owned subsidiary of Pfizer, Pfizer and 6 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Spinal Muscular Atrophy Clinical Trials in Springdale — FAQ

Are there spinal muscular atrophy clinical trials in Springdale?

Yes, there are 12 spinal muscular atrophy clinical trials currently recruiting in Springdale, AR. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Springdale?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Springdale research site will contact you about next steps.

Are clinical trials in Springdale free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Springdale studies also compensate for your time and travel.

What spinal muscular atrophy treatments are being tested?

The 12 active trials in Springdale are testing new therapies including novel drugs, biologics, and treatment approaches for spinal muscular atrophy.

Data updated October 19, 2026 from ClinicalTrials.gov